Skip to main content
Abliva logo

Abliva — Investor Relations & Filings

Ticker · ABLI ISIN · SE0002575340 LEI · 5493005YV22OTMUHZ183 ST Manufacturing
Open in API
Filings indexed 594 across all filing types
Latest filing 2013-10-09 Board/Management Inform…
Country SE Sweden
Listing ST ABLI

About Abliva

https://abliva.com

Abliva is a biopharmaceutical company that discovers and develops medicines for the treatment of primary mitochondrial diseases. These are rare, congenital, and often severe genetic disorders that occur when the cell's energy converters, the mitochondria, are dysfunctional. The company's research and development is focused on creating novel therapies aimed at restoring mitochondrial function and addressing the significant unmet medical needs of patients. Abliva's primary goal is to deliver treatments that provide meaningful clinical benefits for individuals suffering from these debilitating conditions.

Recent filings

Filing Released Lang Actions
Catharina Johansson utsedd till ny CFO, tillträder den 1 december
Board/Management Information Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and announces a specific management change: the appointment of Catharina Johansson as the new CFO, effective December 1st. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in senior management. The document is short and serves as an immediate announcement rather than a comprehensive report (like 10-K or IR).
2013-10-09 Swedish
Catharina Johansson appointed new CFO, effective 1 December
Board/Management Information Classification · 1% confidence The document is explicitly titled "NEWS RELEASE" and announces a change in senior management: the appointment of a new CFO, Catharina Johansson, effective December 1st, and notes the departure of the previous CFO. This directly matches the definition for Board/Management Information (MANG), which covers announcements of changes in senior management.
2013-10-09 English
800 patienter inkluderade i europeisk fas III-studie med CicloMulsion®
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) and is dated 2013-09-09. It announces an operational update regarding the inclusion of 800 patients in a Phase III clinical trial (CIRCUS-studie) for CicloMulsion®. It also provides status updates on other drug candidates (NeuroSTAT®, NVP018/BC556) and concludes with a statement that the company is obligated to publish the information according to securities market law, and that the information was released at a specific time. This structure—a brief announcement detailing recent operational progress, often summarizing key data points without being a full financial report or transcript—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full quarterly/annual report (10-K or IR) and focuses on operational milestones rather than just financial results highlights (ER), it fits best as a general regulatory announcement or press release. Given the options, 'Regulatory Filings' (RNS) is the most appropriate general category for non-standard, time-sensitive operational updates that are mandated disclosures but don't fit the specific financial report codes.
2013-09-09 Swedish
Fortsatta framsteg för NeuroVives satsning i Kina
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESSMEDDELANDE" (Press Release) multiple times and is dated September 5, 2013. It details ongoing business activities, partnership progress in China (with Sihuan Pharmaceutical), participation in a medical conference, and updates on clinical trials (NeuroSTAT®, CicloMulsion®). This content structure—a brief announcement summarizing recent operational and strategic developments, often referencing external reports (like Sihuan's half-year report)—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it is not a full, comprehensive financial report (like a 10-K or IR), and it focuses on operational highlights and progress rather than just announcing a report's publication, the most fitting category is Earnings Release (ER), as these often accompany or summarize the period's performance contextually. It is not a formal regulatory filing like 10-K, nor is it a transcript or a specific legal notice. Given the context of reporting on progress related to a period (mentioning Sihuan's H1 2013 report), ER is the best fit among the specific options.
2013-09-05 Swedish
Major Shareholding Notification 2013
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Avanza Pension) involving a 'Sell' transaction, resulting in the holding falling below a specified threshold (15%). The structure includes 'Before the transaction' and 'After the transaction' tables showing share quantities and voting rights percentages. This content directly corresponds to a notification regarding changes in significant share ownership levels, which matches the definition for Major Shareholding Notification (MRQ). The document is short and appears to be the notification itself, not an announcement of a report.
2013-08-30 English
Major Shareholding Notification 2013
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Avanza Pension) in the issuer (Abliva AB). It explicitly states the 'Reason for major shareholding notification Buy' and provides 'Before the transaction' and 'After the transaction' share counts, resulting in a new total voting rights percentage of 15%. This directly corresponds to the definition of a Major Shareholding Notification.
2013-08-29 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.